Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

1.0K
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
1.0K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.6K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

956
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
956

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of surgical training on patient safety in low-middle-income countries.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Barriers to implementing simulation-based surgical training for improving quality and safety in developing countries: A short communication.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Identification of novel pyrazole-containing thiazolidine-2,4-dione derivatives as potent α-glucosidase inhibitors: design, synthesis and antidiabetic assessment.

Bioorganic chemistry·2026
Same author

Epidemiology and risk factors of surgical site infections in elective surgeries in Pakistan (2022-2023): a multicentre, prospective cohort study from PakSurg 1.

The Lancet regional health. Southeast Asia·2026
Same author

EVs from Stem Cells Improve Mitochondrial Dysfunction in Neuronal Disorders.

Molecular neurobiology·2025
Same author

Resecting Beyond the Central Pelvic Compartment in Pelvic Exenterations for Gynaecological Malignancies: Outcomes From a Tertiary Unit.

The Australian & New Zealand journal of obstetrics & gynaecology·2025

Related Experiment Video

Updated: Apr 25, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K

Heterocyclic GABAA Receptor Modulators: Emerging Therapeutic Strategies for Epilepsy Management.

Shagufi Nazar1, Nadeem Siddiqui1, Mukund Jha1

  • 1Department of Pharmaceutical Chemistry, Medicinal Chemistry and Molecular Modelling Lab, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.

Chemistry & Biodiversity
|April 24, 2026
PubMed
Summary

New anticonvulsant drugs targeting the GABAA receptor show promise for drug-resistant epilepsy. Research focuses on heterocyclic compounds with improved selectivity and reduced side effects for better epilepsy treatment.

Keywords:
AEDsGABAA receptorsdrug resistance epilepsyheterocyclicsmolecular dockingpharmacokinetics

More Related Videos

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

19.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Related Experiment Videos

Last Updated: Apr 25, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

8.0K
Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
07:51

Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors

Published on: November 14, 2014

19.5K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Epilepsy affects many patients with drug-resistant forms, necessitating novel treatments.
  • The γ-aminobutyric acid (GABA) system, especially GABAA receptors, is a key target for anticonvulsant drug development due to its inhibitory role.

Purpose of the Study:

  • To review next-generation GABAA receptor modulators for epilepsy.
  • To analyze their mechanisms, selectivity, and structure-activity relationships.

Main Methods:

  • Systematic literature search (2018-2024) in PubMed, Scopus, and Web of Science.
  • Analysis of pharmacological mechanisms, receptor subtype selectivity, and structure-activity relationships.
  • Review of molecular design, docking studies, and in vivo evaluations.

Main Results:

  • Heterocyclic scaffolds (e.g., benzodiazepines, imidazoles, thiazoles) show anticonvulsant potential.
  • Specific molecular modifications enhance receptor affinity, blood-brain barrier penetration, and metabolic stability.
  • Promising compounds exhibit selective receptor binding and fewer side effects.

Conclusions:

  • Next-generation GABAA receptor modulators offer a promising avenue for treating drug-resistant epilepsy.
  • Further research should focus on efficient design, selective binding evaluation, and clinical trials for advanced anticonvulsants.